 |
Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-121 in Combination With Exemestane in Breast Cancer
May 23, 2013
|
11.5 KB |
|
| |
CAMBRIDGE, Mass., May 23, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) announced today that the last patient has been enrolled in a Phase 2 randomized, double blind clinical trial of MM-121 in combination with exemestane in postmenopausal women with locally advanced or metastatic estrogen receptor positive (ER+) and/or pro...
|
|
Merrimack Reports First Quarter 2013 Financial Results
May 13, 2013
|
22.7 KB |
|
| |
CAMBRIDGE, Mass., May 13, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK), a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of cancer, today announced its first quarter 2013 financial results.
"We continue to exe...
|
|
Merrimack to Present at Multiple Investor Conferences This Spring
May 2, 2013
|
10.7 KB |
|
| |
CAMBRIDGE, Mass., May 2, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that their management team is scheduled to present at multiple investor conferences this spring.
Bank of America Merrill Lynch Healthcare Conference
Date: Tuesday, May 14, 2:20 p.m. PT
Venue: Encore at the ...
|
|
Merrimack Pharmaceuticals Announces Timing of First Quarter 2013 Investor Conference Call
Apr 30, 2013
|
9.2 KB |
|
| |
CAMBRIDGE, Mass., April 30, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that the company will host its First Quarter 2013 Investor Conference Call and webcast at 11 a.m., Eastern time, on Monday, May 13.
The call will cover an update on Merrimack's progress as well as a summary of first quarter fin...
|
|
Merrimack Pharmaceuticals Completes Enrollment of Second Cohort in Phase 2 Study of MM-121 in Non-Small Cell Lung Cancer
Apr 29, 2013
|
11.9 KB |
|
| |
CAMBRIDGE, Mass., April 29, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) announced today that the last patient has been enrolled in the second cohort of a randomized, three-cohort Phase 2 clinical trial of MM-121 in combination with erlotinib for the treatment of non-small cell lung cancer (NSCLC) patients. Developed in co...
|
|
Merrimack Pharmaceuticals Completes Enrollment of One Cohort in Neoadjuvant Phase 2 Study of MM-121 in HER2-Negative Breast Cancer
Apr 15, 2013
|
11.9 KB |
|
| |
CAMBRIDGE, Mass., April 15, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) announced today that the last patient has been enrolled in one group of a two-cohort randomized Phase 2 clinical trial of MM-121 combined with paclitaxel in the neoadjuvant setting of HER2-negative breast cancer. Developed in collaboration with Sanofi...
|
|
Merrimack Pharmaceuticals' Preclinical Research Shows MM-111 Restores Sensitivity To Chemotherapy And HER2-targeted Treatment In Gastric Cancer Model
Apr 10, 2013
|
11.4 KB |
|
| |
CAMBRIDGE, Mass., April 10, 2013 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced preclinical study results showing that the novel bispecific therapy MM-111 restored tumor sensitivity to the chemotherapy agent, paclitaxel, and HER2-targeted treatment, trastuzumab, in a HER2+ gastric cancer model. The research was prese...
|
|
Merrimack Pharmaceuticals' Preclinical Research Shows MM-121 Restores Sensitivity to Anti-Estrogen Therapy and Delays Onset of Treatment Resistance in ER-Positive Breast Cancer Model
Apr 8, 2013
|
11.9 KB |
|
| |
CAMBRIDGE, Mass., April 8, 2013 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced preclinical study results showing that the novel therapy MM-121 restores tumor sensitivity and delays the onset of resistance to the aromatase inhibitor, letrozole, in an ER+ breast cancer model. The study was presented as part of the Amer...
|
|
Merrimack Pharmaceuticals Announces Webcast of Inaugural Research & Development Day
Apr 5, 2013
|
9.5 KB |
|
| |
CAMBRIDGE, Mass., April 5, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that it will hold its inaugural Research & Development Day for analysts and the investor community on Thursday, April 11, 2013 from 9:30 a.m. to 1:00 p.m. ET. Members of Merrimack's management team will provide in-depth reviews of the c...
|
|
Merrimack Pharmaceuticals Announces Top-Line Results From A Single Arm Phase 2 Advanced Lung Cancer Study In Patients With Resistance To An Anti-EGFR Tyrosine Kinase Inhibitor
Apr 4, 2013
|
11.8 KB |
|
| |
CAMBRIDGE, Mass., April 4, 2013 /PRNewswire-USNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) today announced that one cohort of a Phase 2 non-small cell lung cancer (NSCLC) study did not meet its primary endpoint. The cohort evaluated MM-121 in combination with erlotinib to treat patients with NSCLC whose disease progressed on an anti-E...
|
|
Merrimack Pharmaceuticals To Present Preclinical Research On Five Novel Cancer Therapies
Apr 2, 2013
|
12.3 KB |
|
| |
CAMBRIDGE, Mass., April 2, 2013 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced that research data on five novel experimental cancer therapies (MM-398, MM-121, MM-111, MM-302, and MM-141) will be presented at the 2013 American Association for Cancer Research (AACR) Annual Meeting, April 6-10, 2013 in Washington, DC. ...
|
|
Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-121 in Combination With Paclitaxel in Patients With Platinum-Resistant or Refractory Advanced Ovarian Cancers
Mar 18, 2013
|
11.1 KB |
|
| |
CAMBRIDGE, Mass., March 18, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) announced today that the last patient has been enrolled in a Phase 2, open-label, randomized clinical trial of MM-121, a fully human monoclonal antibody that targets ErbB3, in combination with paclitaxel (Taxol®) versus paclitaxel alone in patien...
|
|
Merrimack Reports Fourth Quarter and Full Year 2012 Financial Results
Mar 14, 2013
|
24.5 KB |
|
| |
Enters 2013 With Six Novel Therapeutic Candidates in Clinical Development, Including Phase 3 and Phase 2 Trials in Multiple Cancer Indications
Progress Made in 2012 Puts Merrimack in Position for Robust Set of Milestones in 2013
CAMBRIDGE, Mass., March 14, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK), a bio...
|
|
Merrimack Pharmaceuticals Announces Timing of Fourth Quarter 2012 Investor Conference Call
Feb 27, 2013
|
9.3 KB |
|
| |
CAMBRIDGE, Mass., Feb. 27, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that the company will host its Fourth Quarter 2012 Investor Conference Call and webcast at 10 a.m., Eastern time, on Thursday, March 14.
The call will cover an update on Merrimack's progress as well as a summary of fourth quarte...
|
|
Merrimack to Present at the Cowen and Company 33rd Annual Health Care Conference
Feb 25, 2013
|
9.6 KB |
|
| |
CAMBRIDGE, Mass., Feb. 25, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that Robert Mulroy, President & CEO, is scheduled to present at the Cowen and Company 33rd Annual Health Care Conference on Wednesday, March 6, 2013 at 8:00 a.m. (ET) at the Boston Marriott Copley Place in Boston, Massachusetts.
...
|
|
Merrimack to Participate in Pancreatic Cancer Panel at the 2013 BIO CEO & Investor Conference
Feb 7, 2013
|
10.0 KB |
|
| |
CAMBRIDGE, Mass., Feb. 7, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that Peter Laivins, Vice President of Late Stage Clinical Development and Project Leader for MM-398, will serve as a panelist in the "Oncology: Pancreatic Cancer" panel at the BIO CEO & Investor Conference on Monday, February 11, 2013 at...
|
|
Merrimack Pharmaceuticals to Present Preclinical Data on Bispecific Antibody MM-111 in ErbB2-Positive Gastric Cancers
Jan 23, 2013
|
11.7 KB |
|
| |
CAMBRIDGE, Mass., Jan. 23, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) announced today that preclinical data regarding the bispecific antibody MM-111 will be presented at the American Society of Clinical Oncology 2013 Gastrointestinal Cancers Symposium (ASCO GI), January 24-26, 2013 in San Francisco.
MM-111 is des...
|
|
Merrimack Pharmaceuticals Initiates Cross-Tumor Study to Investigate Potential Predictive Response Markers for a Developmental Nanotherapeutic Chemotherapy
Dec 19, 2012
|
13.4 KB |
|
| |
CAMBRIDGE, Mass., Dec. 19, 2012 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced enrollment of its first patient in a cross indication translational study. The study is designed to identify predictive biomarkers associated with the novel compound MM-398 in advanced colorectal, lung and triple-negative breast cancers...
|
|
Merrimack Pharmaceuticals Initiates Phase 1 Clinical Study of MM-141 in Patients With Advanced Solid Tumors
Dec 12, 2012
|
11.7 KB |
|
| |
CAMBRIDGE, Mass., Dec. 12, 2012 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced enrollment of its first patient in a Phase 1 clinical study of a novel compound for the treatment of advanced solid tumors. MM-141 is a fully human tetravalent antibody designed to target signaling of the P13K/AKT/mTOR pathway driven th...
|
|
Merrimack Pharmaceuticals Presents Promising Phase I Clinical Data for Novel Agent to Treat HER2-positive Breast Cancer and Preclinical Data on Companion Diagnostic
Dec 10, 2012
|
15.2 KB |
|
| |
CAMBRIDGE, Mass., Dec. 10, 2012 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced Phase I clinical trial results for MM-302, the company's novel agent for the treatment of advanced HER2 positive (HER2+ or ErbB2+) breast cancer. The findings demonstrated preliminary safety and tolerability. A study of its potential compa...
|
|
|
Delicious
Digg
Facebook
LinkedIn
Twitter
